AbbVie’s Allergan, Molecular Partners hit by FDA eye drug rejection

This post was originally published on this site

When you spend $63 billion on a company, your hope is that investment will come back; sometimes, however, you get hit with problems. AbbVie is learning that this week after its buyout of Allergan has seen, just a month after finalizing the deal with the …

Click here to read full article